<!DOCTYPE html>
<html lang="pt-BR">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diabetes Mellitus (SBD 2025)</title>
    <link rel="stylesheet" href="style.css">
    <style>
        /* TEMA AZUL (DIABETES) */
        :root { --theme-dm: #1565C0; } 
        
        .resumo-box {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 2px 6px rgba(0,0,0,0.04);
            border-left: 5px solid var(--theme-dm);
        }

        .res-header { 
            font-size: 1.1rem; 
            font-weight: 800; 
            margin-bottom: 15px; 
            display: flex; 
            align-items: center; 
            gap: 10px; 
            color: #0D47A1; 
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 1px solid #E3F2FD;
            padding-bottom: 10px;
        }

        .res-content { font-size: 0.95rem; color: #444; line-height: 1.6; }
        
        /* Tabelas */
        .table-custom { width: 100%; border-collapse: collapse; margin: 10px 0; font-size: 0.85rem; }
        .table-custom th { background-color: #E3F2FD; color: #0D47A1; padding: 8px; text-align: left; border: 1px solid #BBDEFB; }
        .table-custom td { padding: 8px; border: 1px solid #eee; }
        .table-custom tr:nth-child(even) { background-color: #FAFAFA; }

        /* Drugs */
        .drug-table { width: 100%; font-size: 0.85rem; margin-bottom: 20px; border-collapse: collapse; }
        .drug-table th { background: #ECEFF1; color: #37474F; text-align: left; padding: 8px; border-bottom: 2px solid #CFD8DC; }
        .drug-table td { border-bottom: 1px solid #eee; padding: 8px; vertical-align: top; }
        .drug-name { font-weight: 700; color: #1565C0; display: block; font-size: 0.9rem; }
        .drug-class-header { background: #E1F5FE; color: #0277BD; padding: 8px; font-weight: bold; border-left: 4px solid #0288D1; margin-top: 15px; }

        /* TAG SUS */
        .tag-sus { 
            background-color: #2E7D32; color: white; 
            padding: 3px 8px; border-radius: 4px; 
            font-size: 0.75rem; font-weight: bold; 
            display: inline-block; margin-left: 5px;
            vertical-align: text-bottom;
        }

        /* Section Dividers */
        .section-title { 
            background: var(--theme-dm); color: white; 
            padding: 10px 15px; border-radius: 8px; 
            font-weight: bold; margin: 30px 0 15px 0; 
            text-align: center; text-transform: uppercase;
            box-shadow: 0 4px 6px rgba(21, 101, 192, 0.2);
        }

        /* Check lists */
        .check-list li { margin-bottom: 6px; }
        .check-list li::before { content: "‚Ä¢ "; color: var(--theme-dm); font-weight: bold; }

        /* Risco CV DM2 */
        .risk-cv-table td { font-weight: 500; vertical-align: top; }
        .risk-vhigh { border-left: 5px solid #b71c1c; background: #ffebee; }
        .risk-high { border-left: 5px solid #f57f17; background: #fffde7; }
        .risk-mod { border-left: 5px solid #2e7d32; background: #e8f5e9; }

        /* CALCULADORA & BOXES */
        .calc-wrapper { background: #F1F8E9; padding: 20px; border-radius: 10px; border: 1px solid #C5E1A5; margin-top: 20px; text-align: center; }
        .calc-input { padding: 10px; font-size: 1rem; width: 120px; text-align: center; border: 2px solid #AED581; border-radius: 6px; margin-right: 10px; }
        .calc-btn { padding: 10px 20px; font-size: 1rem; background: #558B2F; color: white; border: none; border-radius: 6px; cursor: pointer; font-weight: bold; }
        .calc-btn:hover { background: #33691E; }
        .calc-result { margin-top: 20px; display: none; text-align: left; background: white; padding: 15px; border-radius: 8px; border: 1px solid #ddd; }
        .result-row { display: flex; justify-content: space-between; padding: 8px 0; border-bottom: 1px dashed #eee; font-size: 0.9rem; }
        .result-row strong { color: #2E7D32; }
        
        .calc-box { background: #F5F5F5; border: 1px dashed #999; padding: 10px; margin-top: 5px; border-radius: 6px; font-family: monospace; font-size: 0.85rem; color: #333; }

        /* Did√°tico */
        .didactic-card { background: #E3F2FD; border-radius: 8px; padding: 15px; margin-bottom: 15px; border-left: 5px solid #1565C0; }
        .didactic-title { font-weight: bold; color: #0D47A1; margin-bottom: 5px; display: block; }

        /* Algoritmo Boxes */
        .algo-step { background: #FAFAFA; border: 1px solid #ddd; border-radius: 8px; padding: 15px; margin-bottom: 15px; }
        .algo-title { font-weight: 800; color: #1565C0; display: block; margin-bottom: 5px; text-transform: uppercase; font-size: 0.85rem; }

        .ref-section { margin-top: 40px; font-size: 0.75rem; color: #777; border-top: 1px solid #ddd; padding-top: 20px; }
    </style>
</head>
<body>

    <header class="app-header">
        <button class="back-btn" onclick="window.location.href='resumos.html'">‚¨Ö</button>
        <div class="app-title">Diabetes Mellitus (SBD 2025)</div>
    </header>

    <div class="container">

        <div class="resumo-box">
            <div class="res-header">ü§í Quadro Cl√≠nico T√≠pico</div>
            <div class="res-content">
                <div style="display:flex; gap:20px; flex-wrap:wrap;">
                    <div style="flex:1; min-width:250px;">
                        <strong style="color:#D32F2F;">Diabetes Tipo 1 (DM1)</strong>
                        <p style="font-size:0.9rem;">In√≠cio abrupto, geralmente em crian√ßas/adolescentes. Sintomas cl√°ssicos intensos (4 Ps): <strong>Poli√∫ria, Polidipsia, Polifagia e Perda de peso</strong> inexplicada. Comum abertura com Cetoacidose Diab√©tica (CAD).</p>
                    </div>
                    <div style="flex:1; min-width:250px;">
                        <strong style="color:#1565C0;">Diabetes Tipo 2 (DM2)</strong>
                        <p style="font-size:0.9rem;">In√≠cio insidioso e muitas vezes assintom√°tico. Diagn√≥stico frequentemente por rastreamento. Quando sintom√°tico: poli√∫ria, vis√£o turva, infec√ß√µes de repeti√ß√£o, cicatriza√ß√£o lenta. Associado a S√≠ndrome Metab√≥lica (Obesidade, HAS).</p>
                    </div>
                </div>
            </div>
        </div>

        <div class="section-title">üìä Diagn√≥stico e Metas</div>

        <div class="resumo-box">
            <div class="res-header">ü©∏ Crit√©rios Diagn√≥sticos</div>
            <div class="res-content">
                <p>Necess√°ria confirma√ß√£o com segunda dosagem, exceto se sintomas inequ√≠vocos + Glicemia &ge; 200.</p>
                <table class="table-custom">
                    <tr><th>Categoria</th><th>Jejum</th><th>TOTG 1h (75g)</th><th>TOTG 2h (75g)</th><th>HbA1c</th></tr>
                    <tr><td><strong>Normoglicemia</strong></td><td>< 100</td><td>-</td><td>< 140</td><td>< 5,7%</td></tr>
                    <tr><td><strong>Pr√©-Diabetes</strong></td><td>100 ‚Äì 125</td><td>-</td><td>140 ‚Äì 199</td><td>5,7 ‚Äì 6,4%</td></tr>
                    <tr><td><strong>Diabetes (Geral)</strong></td><td>&ge; 126</td><td>-</td><td>&ge; 200</td><td>&ge; 6,5%</td></tr>
                    <tr style="background:#FFF8E1;"><td><strong>Diabetes Gestacional</strong></td><td>&ge; 92</td><td>&ge; 180</td><td>&ge; 153</td><td>-</td></tr>
                </table>
                <p style="font-size:0.8rem; color:#555;">*Para DMG, basta 1 ponto alterado para diagn√≥stico.</p>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üéØ Metas Terap√™uticas Completas</div>
            <div class="res-content">
                <table class="table-custom">
                    <tr>
                        <th width="30%">Perfil</th>
                        <th>HbA1c</th>
                        <th>Jejum/Pr√©-prandial</th>
                        <th>P√≥s-prandial (2h)</th>
                        <th>Tempo no Alvo (TIR)<br><small>(70-180 mg/dL)</small></th>
                    </tr>
                    <tr>
                        <td><strong>Adulto Geral</strong></td>
                        <td>< 7,0%</td>
                        <td>80 ‚Äì 130</td>
                        <td>< 180</td>
                        <td>> 70%</td>
                    </tr>
                    <tr>
                        <td><strong>Jovem / Sem risco</strong></td>
                        <td>< 6,5%</td>
                        <td>< 110</td>
                        <td>< 140</td>
                        <td>> 70%</td>
                    </tr>
                    <tr>
                        <td><strong>Idoso Fr√°gil / Comorbidades</strong></td>
                        <td>< 8,0 ‚Äì 8,5%</td>
                        <td>< 150 (Flex√≠vel)</td>
                        <td>< 200 (Flex√≠vel)</td>
                        <td>> 50%</td>
                    </tr>
                    <tr>
                        <td><strong>Gestante</strong></td>
                        <td>< 6,0%</td>
                        <td>< 95</td>
                        <td>< 140 (1h) / < 120 (2h)</td>
                        <td>> 70% (63-140)</td>
                    </tr>
                </table>
            </div>
        </div>

        <div class="section-title">üß¨ Diabetes Tipo 1 e Insulinoterapia</div>

        <div class="resumo-box">
            <div class="res-header">üîç Rastreamento e Exames</div>
            <div class="res-content">
                <table class="table-custom">
                    <tr><th>Exame</th><th>Significado Cl√≠nico</th></tr>
                    <tr><td><strong>Anti-GAD 65</strong></td><td>Principal marcador em adultos (LADA) e adolescentes. Persiste por longa data.</td></tr>
                    <tr><td><strong>Anti-IA2 / ZnT8</strong></td><td>Indicam destrui√ß√£o beta r√°pida. Mais comuns em crian√ßas e in√≠cio agudo.</td></tr>
                    <tr><td><strong>Pept√≠deo C</strong></td><td>Mede a produ√ß√£o residual de insulina. <br>Baixo (< 0,5 ng/mL) confirma DM1. Normal/Alto sugere DM2/MODY.</td></tr>
                </table>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üíâ C√°lculo de Dose (M√©todo Fisiol√≥gico)</div>
            <div class="res-content">
                
                <div class="didactic-card">
                    <span class="didactic-title">üí° Entendendo o Esquema Basal-Bolus</span>
                    <p style="margin-bottom:10px;">Imagine a insulina como o combust√≠vel do corpo:</p>
                    <ul style="margin-left:20px;">
                        <li style="margin-bottom:5px;"><strong>Basal (O Fundo):</strong> √â a insulina que mant√©m o motor ligado 24h. Cobre a produ√ß√£o hep√°tica de glicose. Sem ela, a glicemia sobe mesmo em jejum. Aplica-se 1 ou 2 vezes ao dia.</li>
                        <li><strong>Bolus (A Refei√ß√£o):</strong> √â a acelera√ß√£o extra quando voc√™ come. Cobre os carboidratos daquela refei√ß√£o espec√≠fica. Aplica-se antes do caf√©, almo√ßo e jantar.</li>
                    </ul>
                </div>

                <p>M√©todo fisiol√≥gico (Basal-Bolus) para DM1 ou DM2 insulinopenico.</p>

                <h4 style="color:#0277BD; margin-bottom:5px;">1. Dose Total Di√°ria (DTD)</h4>
                <p>DTD Estimada = Peso (kg) x 0,55<br>
                Exemplo: 70kg x 0,55 = 38 unidades/dia.</p>

                <h4 style="color:#0277BD; margin-bottom:5px; margin-top:15px;">2. Distribui√ß√£o da Dose</h4>
                <p><strong>Basal (40-50%):</strong> Mant√©m glicemia nos jejuns. (Ex: 19u)<br>
                <strong>Bolus (50-60%):</strong> Cobre refei√ß√µes. (Ex: 19u divididas nas refei√ß√µes)</p>

                <h4 style="color:#0277BD; margin-bottom:5px; margin-top:15px;">3. Raz√£o Insulina:Carboidrato (Regra dos 500)</h4>
                <p>500 √∑ DTD = Gramas de Carboidrato cobertos por 1 unidade.<br>
                Ex: 500 √∑ 38 ‚âà 13g. (1 ui cobre 13g de CHO)</p>

                <h4 style="color:#0277BD; margin-bottom:5px; margin-top:15px;">4. Fator de Sensibilidade (Regra dos 1800)</h4>
                <p>1800 √∑ DTD = Queda na glicemia (mg/dL) por 1 unidade (Insulina R√°pida).<br>
                Ex: 1800 √∑ 38 ‚âà 47 mg/dL. (1 ui baixa a glicemia em 47 mg/dL)</p>

                <div class="calc-wrapper">
                    <h4 style="color:#33691E; margin-bottom:10px;">üßÆ Calculadora R√°pida (0,55 UI/kg)</h4>
                    <input type="number" id="weightInput" class="calc-input" placeholder="Peso (kg)">
                    <button class="calc-btn" onclick="calculateInsulin()">Calcular</button>

                    <div id="resultArea" class="calc-result">
                        <div class="result-row"><span>Dose Total Di√°ria (DTD):</span> <strong id="resDTD">-</strong></div>
                        <div class="result-row"><span>Insulina Basal (50%):</span> <strong id="resBasal">-</strong></div>
                        <div class="result-row"><span>Insulina Bolus Total (50%):</span> <strong id="resBolus">-</strong></div>
                        <div class="result-row" style="background:#F1F8E9;"><span>Bolus por Refei√ß√£o (aprox):</span> <strong id="resMeal">-</strong></div>
                        <div class="result-row"><span>Rela√ß√£o Insulina:Carboidrato (500/DTD):</span> <strong id="resCarbRatio">-</strong></div>
                        <div class="result-row"><span>Fator de Sensibilidade (1800/DTD):</span> <strong id="resCorrection">-</strong></div>
                        <p style="font-size:0.75rem; color:#777; margin-top:10px;">*Valores estimativos iniciais. Ajuste conforme resposta cl√≠nica.</p>
                    </div>
                </div>

            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üì¶ Tipos de Insulina</div>
            <div class="res-content">
                <div class="drug-class-header">Insulinas Basais</div>
                <table class="drug-table">
                    <tr><th>Insulina</th><th>Dura√ß√£o</th><th>Obs</th></tr>
                    <tr><td><strong>Glargina U100</strong></td><td>24h</td><td>Pico irrelevante. Padr√£o ouro.</td></tr>
                    <tr><td><strong>Glargina U300</strong></td><td>> 24h</td><td>Menor variabilidade.</td></tr>
                    <tr><td><strong>Degludeca</strong></td><td>> 42h</td><td>Flexibilidade de hor√°rio.</td></tr>
                    <tr><td><strong>NPH</strong> <span class="tag-sus">SUS</span></td><td>10-16h</td><td>Pico pronunciado (4-10h). Requer 2 a 3 doses/dia.</td></tr>
                </table>

                <div class="drug-class-header">Insulinas Bolus (R√°pida/Ultrarr√°pida)</div>
                <table class="drug-table">
                    <tr><th>Insulina</th><th>In√≠cio</th><th>Aplica√ß√£o</th></tr>
                    <tr><td><strong>Lispro / Asparte / Glulisina</strong></td><td>5-15 min</td><td>15 min antes da refei√ß√£o.</td></tr>
                    <tr><td><strong>Fiasp</strong></td><td>2-5 min</td><td>Imediatamente antes ou ap√≥s refei√ß√£o.</td></tr>
                    <tr><td><strong>Regular (R)</strong> <span class="tag-sus">SUS</span></td><td>30-60 min</td><td>30-45 min antes da refei√ß√£o (Essencial respeitar tempo).</td></tr>
                </table>
            </div>
        </div>

        <div class="section-title">üíä Diabetes Tipo 2 (DM2)</div>

        <div class="resumo-box">
            <div class="res-header">‚öñÔ∏è Estratifica√ß√£o de Risco CV (Completa)</div>
            <div class="res-content">
                <p>Fundamental para escolha da terapia. (SBD 2025)</p>
                <table class="table-custom risk-cv-table">
                    <tr>
                        <th width="25%">Risco</th>
                        <th>Crit√©rios</th>
                    </tr>
                    <tr class="risk-vhigh">
                        <td><strong>MUITO ALTO</strong></td>
                        <td>
                            <strong>Doen√ßa Cardiovascular Estabelecida:</strong><br>
                            ‚Ä¢ IAM, AVC, DAOP, Revasculariza√ß√£o, Estenose carot√≠dea > 50%, Aneurisma Aorta, HVE grave.<br>
                            <strong>OU Les√£o de √ìrg√£o Alvo (LOA) Grave:</strong><br>
                            ‚Ä¢ TFG < 45 ml/min.<br>
                            ‚Ä¢ TFG 45-60 + Albumin√∫ria (A3 ou A2).<br>
                            ‚Ä¢ Retinopatia avan√ßada.<br>
                            <strong>OU &ge; 3 Fatores de Risco</strong> (Idade, HAS, Tabagismo, Dislipidemia, Obesidade).
                        </td>
                    </tr>
                    <tr class="risk-high">
                        <td><strong>ALTO</strong></td>
                        <td>
                            ‚Ä¢ DM com dura√ß√£o <strong>> 10 anos</strong> (sem DCV).<br>
                            ‚Ä¢ OU Presen√ßa de <strong>1 ou 2 Fatores de Risco</strong> adicionais.<br>
                            ‚Ä¢ OU LOA incipiente (Albumin√∫ria A2 isolada).
                        </td>
                    </tr>
                    <tr class="risk-mod">
                        <td><strong>MODERADO</strong></td>
                        <td>
                            ‚Ä¢ DM diagn√≥stico recente (< 10 anos).<br>
                            ‚Ä¢ Idade < 50 anos.<br>
                            ‚Ä¢ <strong>SEM</strong> outros fatores de risco ou LOA.
                        </td>
                    </tr>
                </table>
            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">‚öôÔ∏è Manejo e Tratamento (SBD 2025)</div>
            <div class="res-content">
                
                <h4 style="color:#0D47A1; margin-bottom:10px;">1. Estrat√©gia Baseada no Perfil Cl√≠nico</h4>
                <div style="background:#FFEBEE; padding:12px; border-radius:8px; border-left:5px solid #D32F2F; margin-bottom:10px;">
                    <strong>COM DOEN√áA CARDIORRENAL (DCV, IC, DRC):</strong><br>
                    Uso de <strong>iSGLT2</strong> e/ou <strong>GLP-1 RA</strong> com benef√≠cio comprovado √© MANDAT√ìRIO, <u>independente da HbA1c</u>.
                </div>
                <div style="background:#F3E5F5; padding:12px; border-radius:8px; border-left:5px solid #7B1FA2; margin-bottom:20px;">
                    <strong>SEM DOEN√áA CARDIORRENAL:</strong><br>
                    <strong>Foco no Peso:</strong> Tirzepatida > Semaglutida > Liraglutida > iSGLT2.<br>
                    <strong>Foco no Custo (SUS):</strong> Metformina + Sulfonilureia (Gliclazida MR).
                </div>

                <h4 style="color:#0D47A1; margin-bottom:10px;">2. Defini√ß√£o da Estrat√©gia Inicial</h4>
                <div class="algo-step">
                    <span class="algo-title">Monoterapia (HbA1c < 7,5%)</span>
                    <p>Iniciar com <strong>Metformina</strong> (se tolerada).<br>
                    Reavaliar em 3 meses.</p>
                </div>
                <div class="algo-step">
                    <span class="algo-title">Terapia Dupla (HbA1c 7,5% a 9,0%)</span>
                    <p>Iniciar diretamente com <strong>2 f√°rmacos</strong> de classes diferentes.<br>
                    Ex: Metformina + iSGLT2 ou Metformina + GLP-1 RA.</p>
                </div>
                <div class="algo-step" style="border-color:#E57373; background:#FFEBEE;">
                    <span class="algo-title" style="color:#D32F2F;">Insulinoterapia Inicial (HbA1c > 9,0% + Sintomas)</span>
                    <p>Se sintomas catab√≥licos (perda de peso, poli√∫ria) ou glicemia > 300 mg/dL.<br>
                    Pode-se tentar simplificar para oral ap√≥s controle da glicotoxicidade.</p>
                </div>

                <h4 style="color:#0D47A1; margin-bottom:10px; margin-top:20px;">3. Intensifica√ß√£o (Falha Terap√™utica)</h4>
                <ul class="check-list">
                    <li>Se HbA1c fora da meta ap√≥s 3 meses: Adicionar f√°rmaco de outra classe.</li>
                    <li>Preferir <strong>GLP-1 RA injet√°vel</strong> antes de iniciar insulina (maior efic√°cia, menor hipo, perda de peso).</li>
                    <li>Se falha com GLP-1 RA ou contraindica√ß√£o: Iniciar <strong>Insulina Basal</strong> (0,1 a 0,2 UI/kg ao deitar).</li>
                </ul>

            </div>
        </div>

        <div class="resumo-box">
            <div class="res-header">üìö Farmacologia (Classes)</div>
            <div class="res-content">
                
                <div class="drug-class-header">Biguanidas</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Metformina <span class="tag-sus">SUS</span></span></td><td>500 - 2550 mg</td><td>1¬™ linha geral. Suspender se TFG < 30. Defici√™ncia B12 a longo prazo.</td></tr>
                </table>

                <div class="drug-class-header">Sulfonilureias (Secretagogos)</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Gliclazida MR <span class="tag-sus">SUS</span></span></td><td>Preferencial (menor risco hipo e CV).</td></tr>
                    <tr><td><span class="drug-name">Glibenclamida <span class="tag-sus">SUS</span></span></td><td>Evitar (alto risco de hipo grave, especialmente idosos).</td></tr>
                    <tr><td><span class="drug-name">Glimepirida</span></td><td>Op√ß√£o alternativa.</td></tr>
                </table>

                <div class="drug-class-header">Inibidores SGLT2 (Gliflozinas)</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Dose</th><th>Benef√≠cios Extras</th></tr>
                    <tr><td><span class="drug-name">Dapagliflozina</span></td><td>10 mg</td><td>Prote√ß√£o IC e Renal (aprovada para n√£o-diab√©ticos tamb√©m).</td></tr>
                    <tr><td><span class="drug-name">Empagliflozina</span></td><td>10 - 25 mg</td><td>Prote√ß√£o CV, IC e Renal.</td></tr>
                    <tr><td><span class="drug-name">Canagliflozina</span></td><td>100 - 300 mg</td><td>Prote√ß√£o Renal e CV.</td></tr>
                    <tr><td colspan="3"><em>Risco: Infec√ß√£o genital, cetoacidose euglic√™mica.</em></td></tr>
                </table>

                <div class="drug-class-header">Agonistas GLP-1 (Incretinas)</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Frequ√™ncia</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Semaglutida</span></td><td>Semanal (SC) / Di√°rio (Oral)</td><td>Maior pot√™ncia perda peso e HbA1c. Prote√ß√£o CV.</td></tr>
                    <tr><td><span class="drug-name">Liraglutida</span></td><td>Di√°ria</td><td>Perda peso. Prote√ß√£o CV.</td></tr>
                    <tr><td><span class="drug-name">Dulaglutida</span></td><td>Semanal</td><td>Prote√ß√£o CV.</td></tr>
                </table>

                <div class="drug-class-header">Inibidores DPP-4 (Gliptinas)</div>
                <table class="drug-table">
                    <tr><th>F√°rmaco</th><th>Obs</th></tr>
                    <tr><td><span class="drug-name">Sitagliptina / Vildagliptina</span></td><td>Neutros no peso. Baixo risco hipo. Pot√™ncia fraca.</td></tr>
                    <tr><td><span class="drug-name">Linagliptina</span></td><td>N√£o requer ajuste renal (seguro em di√°lise).</td></tr>
                </table>

            </div>
        </div>

        <div class="ref-section">
            <strong>Refer√™ncias Bibliogr√°ficas:</strong><br>
            Diretrizes da Sociedade Brasileira de Diabetes 2025-2026. Dispon√≠vel em: diretriz.diabetes.org.br.<br>
            UCSF Diabetes Teaching Center (Calculating Insulin Dose).
        </div>

    </div>

    <script>
        function calculateInsulin() {
            let weight = parseFloat(document.getElementById('weightInput').value);
            
            if (!weight || weight <= 0) {
                alert("Por favor, insira um peso v√°lido.");
                return;
            }

            // Fator UCSF: 0.55 u/kg/dia
            let dtd = weight * 0.55;
            let basal = dtd * 0.5;
            let bolusTotal = dtd * 0.5;
            let mealBolus = bolusTotal / 3; // M√©dia 3 refei√ß√µes
            let carbRatio = 500 / dtd;
            let correctionFactor = 1800 / dtd;

            // Renderizar resultados
            document.getElementById('resDTD').innerText = dtd.toFixed(0) + " UI";
            document.getElementById('resBasal').innerText = basal.toFixed(0) + " UI";
            document.getElementById('resBolus').innerText = bolusTotal.toFixed(0) + " UI";
            document.getElementById('resMeal').innerText = "~" + mealBolus.toFixed(0) + " UI";
            document.getElementById('resCarbRatio').innerText = "1 UI para " + carbRatio.toFixed(0) + "g CHO";
            document.getElementById('resCorrection').innerText = "1 UI reduz " + correctionFactor.toFixed(0) + " mg/dL";

            document.getElementById('resultArea').style.display = 'block';
        }
    </script>

</body>
</html>